References
- Banna GL, Collovà E, Gebbia V, et al. (2010). Anticancer oral therapy: emerging related issues. Cancer Treat Rev 36:595–605
- Beasley MB, Franks TJ, Galvin JR, et al. (2002). Acute fibrinous and organizing pneumonia: a histologic pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 126:1064–70
- Benet LZ, Williams RL. (1990). Design and optimization of dosage regimens: pharmacokinetic data. In: Gilman AG, Rall TW, Nies AS, et al., eds. The pharmacological basis of therapeutics. New York: Pergamon, 1650–735
- Canto RFS. (2009). Síntese de diidropirimidinonas análogas ao Monastrol e avalição pré-clínica do LaSOM 65 [dissertação de mestrado]. Porto Alegre: Faculdade de Farmácia/UFRGS
- Canto RFS, Bernardi A, Battastini AMO, et al. (2011). Synthesis of dihydropyrimidin-2-one/thione library and cytotoxic activity against the human U138-MG and rat C6 glioma cell lines. J Braz Chem Soc 22:1379–88
- FDA, Guidance for Industry. Bioanalytical Method Validation (2001). Available from: http://www.fda.gov/cder/guidance [last accessed 28 March 2013]
- Hori R, Okumura K, Yoshida H. (1987). Binding of basic drugs to rat lung mitochondria. Pharmaceut Res 4:142–6
- Huszar D, Theoclitou ME, Skolnik J, Herbest R. (2009). Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 28:197–208
- Kappe CO. (2000). Biologically active dihydropyrimidones of the Biginelli-type – a literature survey. Eur J Med Chem 35:1043–52
- Kurashige S, Mitsuhashi S. (1982). Macrophage activities in sarcoma 180 bearing mice and EL4 bearing mice. Gann Jap J Cancer Res 73:85–90
- Mayer TU, Kapoor TM,Haggarty SJ, et al. (1999). Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286:971–4
- Müller C, Gross D, Sarli V, et al. (2007). Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer Chemothery Pharmacol 59:157–64
- Nix DE, Goodwin SD, Peloquin CA, et al. (1991). Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother 35:1947–52
- OECD. (2001). OECD Guideline for testing of chemicals, Acute Oral Toxicity – Fixed Dose Procedure (420). Available from: http://iccvam.niehs.nih.gov/SuppDocs/FedDocs/OECD/OECD_GL420.pdf [last accessed 25 Jul 2013]
- Olson H, Betton G, Robinson D, et al. (2000). Concordance of toxicity of pharmaceuticals in humans and in animals regulatory. Requl Toxicol Pharmacol 32:56–67
- Panchagnula R, Thomas NS. (2000). Biopharmaceutics and pharmacokinetics in drug research. Int J Pharm 201:131–50
- Peters T, Lindenmaier H, Haefeli WE, Weiss J. (2006). Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn-Schmiedeberg’s Arch of Pharmacol 372:291–9
- Poulin P, Theil FP. (2000). A priori predicition of Tissue:Plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sciences 89:16–35
- Russowsky D, Canto RF, Sanches SA, et al. (2006). Synthesis and differential antiproliferative activity of Biginelli compounds against cancer cell lines: monastrol, oxo-monastrol and oxygenated analogues. Bioorg Chem 34:173–82
- Schmidt M, Bastians H. (2007). Mitotic drug targets and the development of novelanti-mitotic anticancer drugs. Drug Resist Updat 10:162–81
- Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. (2006). Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2:494–503
- Shargel L, Wu-Pong S, Yu ABC. (2005). Applied biopharmaceutics & pharmacokinetics. New York: McGran-Hill
- Taylor G. (1990). The absorption and metabolism of xenobiotics in the lung. Adv Drug Deliver Rev 5:37–61
- Theil FP, Guentert TW, Haddad S, Poulin P. (2003). Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 138:29–49
- Tomaszewski JE, Smith AC, Covey JM, et al. (2002). Relevance of preclinical pharmacology and toxicology to phase I trial extrapolation techniques: relevance of animal toxicology. In: Baguley BC, Kerr DJ, eds. Anticancer drug development. San Diego: Academic Press, 301–28
- Vestal RE, Kornhauser DM, Shand DG. (1980). Active uptake of propranolol by isolated rabbit alveolar macrophages and its inhibition by other basic amines. J Pharmacol Exp Ther 214:106–11